{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:55:08Z","timestamp":1792086908032,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Fundaci\u00f3n Para el Progreso de la Medicina"},{"name":"Instituto Universitario del Hospital Italiano"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.lfs.2020.118979","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T14:47:14Z","timestamp":1610030834000},"page":"118979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma"],"prefix":"10.1016","volume":"268","author":[{"given":"Ang\u00e9lica Mar\u00eda","family":"Gamboa-Cede\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e1ngeles","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Cristaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Schutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorotea","family":"Fantl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Cugliari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Zerga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Rojas-Bilbao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Jauk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hern\u00e1n","family":"Garc\u00eda Rivello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella Maris","family":"Ranuncolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2020.118979_bb0005","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. IARC. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC). Revised 4th edition, vol. 2. Press Lyon, France. 2017. doi: https:\/\/doi.org\/10.1182\/blood-2011-01-293050.","DOI":"10.1182\/blood-2011-01-293050"},{"key":"10.1016\/j.lfs.2020.118979_bb0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin\u2019s lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2020.118979_bb0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.4.110807.092209","article-title":"Pathogenesis of classicalal and lymphocyte-predominant Hodgkin lymphoma","volume":"4","author":"Schmitz","year":"2009","journal-title":"Annu. Rev. Pathol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118979_bb0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pathol.2019.09.005","article-title":"Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis","volume":"52","author":"Piris","year":"2020","journal-title":"Pathology."},{"issue":"1","key":"10.1016\/j.lfs.2020.118979_bb0025","first-page":"7","article-title":"Cancer statistics","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.lfs.2020.118979_bb0030","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ajh.22105","article-title":"Hodgkin Lymphoma: 2020 update on diagnosis, risk-stratification and management","volume":"86","author":"Ansell","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118979_bb0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1200\/JCO.1987.5.1.27","article-title":"Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin\u2019s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy","volume":"5","author":"Santoro","year":"1987","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lfs.2020.118979_bb0040","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/blood-2004-12-4750","article-title":"From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential","volume":"105","author":"Re","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.lfs.2020.118979_bb0045","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1056\/NEJMc1506340","article-title":"PET-directed therapy for Hodgkin\u2019s lymphoma","volume":"373","author":"Radford","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.lfs.2020.118979_bb0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/2040620717728000","article-title":"Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma","volume":"8","author":"Nikolaenko","year":"2017","journal-title":"Ther Adv Hematol."},{"issue":"23","key":"10.1016\/j.lfs.2020.118979_bb0055","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B-cells at various stages of development","volume":"91","author":"K\u00fcppers","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2020.118979_bb0060","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood.V95.4.1443.004k55_1443_1450","article-title":"Hodgkin and Reed Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription","volume":"95","author":"Marafioti","year":"2000","journal-title":"Blood."},{"key":"10.1016\/j.lfs.2020.118979_bb0065","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood-2002-03-0839","article-title":"Loss of the B-lineage specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"101","author":"Schwering","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2020.118979_bb0070","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1182\/blood-2005-09-3765","article-title":"Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma","volume":"107","author":"Ushmorov","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2020.118979_bb0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/annonc\/8.suppl_2.S79","article-title":"Normal and malignant B-cell development with special reference to Hodgkin\u2019s disease","volume":"8","author":"Rajewsky","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2020.118979_bb0080","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0065-230X(02)84009-X","article-title":"Molecular biology of Hodgkin\u2019s lymphoma","volume":"84","author":"K\u00fcppers","year":"2000","journal-title":"Adv. Cancer Res."},{"issue":"2","key":"10.1016\/j.lfs.2020.118979_bb0085","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2002-04-1128","article-title":"Spanish Hodgkin Lymphoma Study Group. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue micro-arrays","volume":"101","author":"Garcia","year":"2003","journal-title":"Blood."},{"issue":"18","key":"10.1016\/j.lfs.2020.118979_bb0090","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1182\/blood-2012-01-405951","article-title":"Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival","volume":"120","author":"Ranuncolo","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.lfs.2020.118979_bb0095","doi-asserted-by":"crossref","unstructured":"Gamboa-Cede\u00f1o AM, Castillo M, Xiao W, Waldmann TA, Ranuncolo SM. Alternative and Canonical NF-kB Pathways DNA-binding Hierarchies Networks Define Hodgkin Lymphoma and Non-Hodgkin Diffuse Large B-cell Lymphoma Respectively. 145 (6): 1437\u20131448. doi:https:\/\/doi.org\/10.1007\/s00432-019-02909-z.","DOI":"10.1007\/s00432-019-02909-z"},{"issue":"6","key":"10.1016\/j.lfs.2020.118979_bb0100","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-mimetic drugs: blazing the trail for new cancer medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lfs.2020.118979_bb0105","doi-asserted-by":"crossref","unstructured":"Rojas-Bilbao E, Knott ME, Bal de Kier Joffe ED, Zerga ME, Nu\u00f1ez M, Puricelli LI, et al. Oct2, BCL6, IRF8, OCA-B and PU.1 in the assessment of prognosis in diffuse large B-cell lymphoma patients. J Mol Biomarkers and Diagnosis. 2016;7\u20132, 276\u2013284. doi: https:\/\/doi.org\/10.4172\/2155-9929.1000276.","DOI":"10.4172\/2155-9929.1000276"},{"issue":"1","key":"10.1016\/j.lfs.2020.118979_bb0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.V68.1.285.285","article-title":"Cytochemical, immunologic, chromosomal and molecular genetic analysis of a novel cell line derived from Hodgkin\u2019s disease","volume":"68","author":"Kamesaki","year":"1986","journal-title":"Blood."},{"key":"10.1016\/j.lfs.2020.118979_bb0115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000112062","article-title":"U-H01, a new cell line derived from a primary refractory classical Hodgkin lymphoma","volume":"119","author":"Mader","year":"2007","journal-title":"Cytogenet Genome Res."},{"issue":"1","key":"10.1016\/j.lfs.2020.118979_bb0120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.1068","article-title":"Cell fusion is not involved in the generation of giant cells in the Hodgkin-Reed Sternberg cell line L1236","volume":"67","author":"Re","year":"2001","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lfs.2020.118979_bb0125","doi-asserted-by":"crossref","unstructured":"Naumovsky L, Ultz PJ, Bergstrom SK, Morgan R, Molina A, Toole JJ, et al. SUP-HD1: a new Hodgkin's disease derived cell line lymphoid features produces interferon \u03b3. Blood. 1989;74:8 2733\u20132742. PMID: 2554995.","DOI":"10.1182\/blood.V74.8.2733.2733"},{"key":"10.1016\/j.lfs.2020.118979_bb0130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-3-642-83781-4_8","article-title":"Characterization of Hodgkin\u2019s disease derived cell line HDLM-2","volume":"117","author":"Drexler","year":"1989","journal-title":"Recent Results Cancer Res."},{"issue":"1","key":"10.1016\/j.lfs.2020.118979_bb0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00405072","article-title":"Hodgkin\u2019s disease: establishment and characterization of four in vitro cell lines","volume":"101","author":"Diehl","year":"1981","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lfs.2020.118979_bb0140","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1515\/hsz-2017-0321","article-title":"Hodgkin lymphoma cell lines: to separate the wheat from the chaff","volume":"399","author":"Drexler","year":"2018","journal-title":"Biol. Chem."},{"issue":"3","key":"10.1016\/j.lfs.2020.118979_bb0145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"issue":"20","key":"10.1016\/j.lfs.2020.118979_bb0150","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL-2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gen expression signatures: a report from the International DLBCL Rituximab-CHOP consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood."},{"issue":"18","key":"10.1016\/j.lfs.2020.118979_bb0155","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax Plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"113","author":"Zelenetz","year":"2019","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.lfs.2020.118979_bb0160","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMra1003733","article-title":"Early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Armitage","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2020.118979_bb0165","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1182\/blood-2007-09-110635","article-title":"Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed\u2013Sternberg cells","volume":"111","author":"Saitoh","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.lfs.2020.118979_bb0170","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2141.2012.09113.x","article-title":"Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma","volume":"157","author":"Otto","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lfs.2020.118979_bb0175","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/cncr.22714","article-title":"Pretransplant positive positron emission tomography\/gallium scans predict poor outcome in patients with recurrent\/refractory Hodgkin lymphoma","volume":"109","author":"Jabbour","year":"2017","journal-title":"Cancer."},{"key":"10.1016\/j.lfs.2020.118979_bb0180","first-page":"1150","article-title":"Prognostic factors in Hodgkin\u2019s disease: multivariate analysis of 327 patients from a single institution","volume":"6","author":"Smolewski","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2020.118979_bb0185","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1046\/j.1365-2559.2000.01010.x","article-title":"Clinical drug-resistant nodular sclerosing Hodgkin\u2019s lymphoma is associated with decreased BCL-2 expression in the surrounding lymphocytes and with increased BCL-2 expression in the Reed-Sternberg cells","volume":"37","author":"van Spronsen","year":"2000","journal-title":"Histopathology."},{"key":"10.1016\/j.lfs.2020.118979_bb0190","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/ajcp\/99.6.663","article-title":"An immunocytochemical study of p53 and BCL-2 protein expression in Hodgkin\u2019s disease","volume":"99","author":"Doussis","year":"1993","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.lfs.2020.118979_bb0195","first-page":"492","article-title":"Hodgkin cells accumulate mRNA for BCL-2","volume":"73","author":"Hell","year":"1995","journal-title":"Lab. Investig."},{"key":"10.1016\/j.lfs.2020.118979_bb0200","first-page":"376","article-title":"Low p53 and high BCL-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin\u2019s disease: involvement of apoptosis resistance?","volume":"11","author":"Brink","year":"1998","journal-title":"Mod. Pathol."},{"issue":"12","key":"10.1016\/j.lfs.2020.118979_bb0205","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1182\/blood.V100.12.3935","article-title":"BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens","volume":"2","author":"Rassidakis","year":"2002","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.lfs.2020.118979_bb0210","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1371\/journal.pone.0006341","article-title":"Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin Lymphoma: a study of 59 cases","volume":"4","author":"Canioni","year":"2009","journal-title":"PlosOne."},{"key":"10.1016\/j.lfs.2020.118979_bb0215","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7150\/jca.4716","article-title":"Primary refractory and relapsed classical Hodgkin lymphoma - significance of differential CD15 expression in Hodgkin-Reed-Sternberg cells","volume":"3","author":"Benharroch","year":"2012","journal-title":"J. Cancer"},{"key":"10.1016\/j.lfs.2020.118979_bb0220","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/1042819021000037958","article-title":"The prognostic relevance of apoptosis-related proteins in classical Hodgkin\u2019s lymphomas","volume":"44","author":"Vassallo","year":"2003","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.lfs.2020.118979_bb0225","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.2005.04.358","article-title":"Expression of BCL-2 in classical Hodgkin\u2019s Lymphoma: an independent predictor of poor outcome","volume":"23","author":"Sup","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.118979_bb0230","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2020.118979_bb0235","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed Death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lfs.2020.118979_bb0240","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL-2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"New Engl J Med."},{"issue":"5","key":"10.1016\/j.lfs.2020.118979_bb0245","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/1060028016685803","article-title":"Venetoclax: a first-in-class Oral BCL-2 inhibitor for the management of lymphoid malignancies","volume":"51","author":"King","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.lfs.2020.118979_bb0250","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11899-017-0359-0","article-title":"The development and current use of BCL-2 inhibitors for the treatment of chronic lymphocytic leukemia","volume":"12","author":"Lampson","year":"2017","journal-title":"Curr Hematol Malig Rep."},{"issue":"9","key":"10.1016\/j.lfs.2020.118979_bb0255","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood-2011-11-391037","article-title":"Experience with obatoclax mesylate (GX15-070), a small molecule pan\u2013BCL-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma","volume":"119","author":"Oki","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.lfs.2020.118979_bb0260","doi-asserted-by":"crossref","unstructured":"Zeping Han, Jiening Liang, Yuguang Li and Jinhua He. Drugs and clinical approaches targeting the antiapoptotic protein: a review. Biomed Res Int. 2019; 2019: 1212369. doi: https:\/\/doi.org\/10.1155\/2019\/1212369.","DOI":"10.1155\/2019\/1212369"},{"key":"10.1016\/j.lfs.2020.118979_bb0265","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphomas","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.lfs.2020.118979_bb0270","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutatios and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lfs.2020.118979_bb0275","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1080\/10428190600667721","article-title":"Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin\u2019s lymphoma","volume":"47","author":"Feuerborn","year":"2006","journal-title":"Leukemia & Lymphoma."},{"key":"10.1016\/j.lfs.2020.118979_bb0280","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.leu.2404565","article-title":"Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin\/Reed-Sternberg cells","volume":"21","author":"Janz","year":"2007","journal-title":"Leukemia."},{"key":"10.1016\/j.lfs.2020.118979_bb0285","unstructured":"Cuceu C. Telomere dysfunction and chromosomal instability in Hodgkin Lymphoma. Cancer. Universit\u00e9 Paris-Saclay. 2015: NNT: 2015SACLS210."},{"issue":"4","key":"10.1016\/j.lfs.2020.118979_bb0290","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/cancers10040091","article-title":"M\u2019Kacher R. Chromosomal instability in Hodgkin Lymphoma: an in depth review and perspectives","volume":"10","author":"Cuceu","year":"2018","journal-title":"Cancers."},{"issue":"7","key":"10.1016\/j.lfs.2020.118979_bb0295","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3390\/biom10071081","article-title":"DLBCL cells with acquired resistance to venetoclax are not sensitized to BIRD-2 but can be resensitized to venetoclax through Bcl-XL inhibition","volume":"10","author":"Kerkhofs","year":"2020","journal-title":"Biomolecules."},{"key":"10.1016\/j.lfs.2020.118979_bb0300","first-page":"1","article-title":"Enhancing venetoclax activity in hematological malignancies","author":"Satta","year":"2020","journal-title":"Expert Opin. Investig. Drugs"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520317392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520317392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:40:57Z","timestamp":1758400857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520317392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":60,"alternative-id":["S0024320520317392"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118979","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"118979"}}